Quantitative Assessment of Ribociclib Exposure–Response Relationship to Justify Dose Regimen in Patients with Advanced Breast Cancer

Abstract

AbstractRibociclib in combination with endocrine therapy (ET) is a globally approved treatment option for patients with hormone receptor‐positive (HR+)/human epidermal growth factor receptor 2‐negative (HER2−) advanced breast cancer (ABC) and has demonstrated significantly improved overall survival (OS) in 3 phase 3 clinical trials. To justify the dose regimen and dose modification scheme for patients with ABC, the pharmacokinetic (PK), safety, and efficacy data of ribociclib were analyzed. The data of several phase 1‐3 clinical studies were pooled and analyzed to characterize the relationship between exposure (dose or PK) and efficacy (progression‐free survival (PFS), time to response, and OS) or safety (neutropenia and QT interval prolongation). The exposure–efficacy analysis showed no apparent relationship between ribociclib exposure and efficacy (PFS and OS), and efficacy analysis by dose reduction showed that patients with ABC continued to benefit from the treatment following dose reduction, supporting the starting dose of 600 mg as well as dose reductions to 400 and 200 mg. The exposure–safety analysis showed that neutropenia and QT prolongation are related to ribociclib exposure that can be effectively managed by individualized dose modification (dose reduction/interruption). Collective evidence from the exposure–response analyses for efficacy and safety support the use of ribociclib in combination with ET partners at the starting dose of 600 mg, and also the effectiveness of individualized dose reductions in managing safety, while maintaining efficacy, in patients with HR+/HER2− ABC. This analysis illustrates the utility of quantitative assessment in justifying dose selection and dose modification for oncology medicines.